pharma.markets

pharma.markets

  • HOME
  • Imprint

Cancer

Bayer expands global clinical program for darolutamide in prostate cancer

23/03/2023 MaP 0

Bayer expands global clinical program for darolutamide in prostate cancer   Phase III study ARASTEP initiated in hormone-sensitive prostate cancer, in patients with high-risk biochemical […]

Nubeqa™ (darolutamide) approved for additional prostate cancer indication in China Nubeqa™ now approved for metastatic hormone-sensitive prostate cancer as well as non-metastatic castration-resistant prostate cancer

20/03/2023 MaP 0

Additional indication based on data from the pivotal Phase III ARASENS trial The Chinese National Medical Products Administration (NMPA) has approved the oral androgen receptor […]

Nubeqa™ (darolutamide) receives EU approval for additional indication in prostate cancer

01/03/2023 MaP 0

European Commission granted approval of Nubeqa™ (darolutamide) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) / Approval is based on Phase III […]

Nubeqa™ approved for additional indication in Japan

27/02/2023 MaP 0

Darolutamide approved for metastatic prostate cancer as well as non-metastatic castration-resistant prostate cancer / New approval based on data from the pivotal Phase III ARASENS […]

National Comprehensive Cancer Network Announces Collaboration with Blood Cancer Experts in Poland

27/02/2023 MaP 0

New international agreement builds on existing work to improve cancer care and outcomes worldwide by adapting and implementing evidence-based guidelines for Poland and beyond. PLYMOUTH […]

Accord Healthcare marks World Cancer Day 2023 appearing in ITN Business news-style programme Working Together: To Tackle Cancer

04/02/2023 MaP 0

Accord Healthcare (Accord), one of Europe’s fastest growing pharmaceutical companies, marks World Cancer Day 2023 today by taking part in news-style programme for ITN Business […]

CHMP recommends Bayer’s darolutamide for the treatment of metastatic hormone-sensitive prostate cancer

27/01/2023 MaP 0

CHMP recommendation is based on Phase III data, which demonstrated that darolutamide plus androgen deprivation therapy (ADT) in combination with docetaxel significantly reduced the risk […]

FDA grants priority review to Roche’s bispecific antibody glofitamab for people with relapsed or refractory large B-cell lymphoma

06/01/2023 MaP 0

Basel, 6 January 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s […]

Targeted Regulatory Measures Increase Safety in Cancer Immunotherapy with CAR-T Cells

19/12/2022 MaP 0

Quote Professor Funk Cancer immunotherapy with CAR-T cells is an important therapeutic strategy for lymphoma and leukaemia, but it can cause serious adverse reactions. Experts […]

Novartis PluvictoTM shows statistically significant and clinically meaningful radiographic progression-free survival benefit in patients with PSMA–positive metastatic castration-resistant prostate cancer

06/12/2022 MaP 0

Ad hoc announcement pursuant to Art. 53 LR Today, Novartis announced the pivotal Phase III PSMAfore study with PluvictoTM (INN: lutetium (177Lu) vipivotide tetraxetan), a […]

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

06/06/2022 MaP 0

Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]

European Stroke Organisation Conference 2022: New study links gut microbiota strains with more severe strokes and poorer post-stroke recovery

04/05/2022 MaP 0

A new study has identified strains of gut microbiota that are associated with more severe strokes and worse post-stroke recovery, revealing that the gut microbiome […]

New imaging method reveals causes of cerebral oedema

31/01/2022 MaP 0

Neurobiology: Publication in the Journal for Neuroscience Cerebral oedema is a dangerous complication in many brain-related conditions such as strokes. Researchers at the Institute of […]

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

10/01/2022 MaP 0

Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against […]

Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data

18/12/2021 MaP 0

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug candidate ATOR-1017, which is […]

Posts navigation

1 2 … 4 »

Translation

Search

Categories

  • Age.related Degeneration
  • Alzheimer
  • Animal health
  • Asthma
  • Bioscience
  • Cancer
  • Conferences
  • Cosmetics
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Food
  • HHS
  • Humanitarian Aid
  • Imprint
  • Influenza
  • Innovation
  • Mental Health
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • Spain
  • Sports
  • Therapy
  • Trade Fair
  • UN
  • Vaccines
  • Valencia Comunidad
  • WHO

Reports

  • BioNTech Announces New ADS Repurchase Program
  • Merck Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry Education
  • Bayer expands global clinical program for darolutamide in prostate cancer
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections

Archive

  • March 2023 (17)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • BioNTech Announces New ADS Repurchase Program

    28/03/2023 0
  • Merck Announces Expanded Partnership with Beyond Benign to Increase Global Access to Green Chemistry Education

    27/03/2023 0
  • Bayer expands global clinical program for darolutamide in prostate cancer

    23/03/2023 0
  • Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation

    21/03/2023 0
  • Pigs as Organ Donors – New Findings on the Prevention of Retrovirus Infections

    20/03/2023 0
Archives
  • March 2023 (17)
  • February 2023 (11)
  • January 2023 (6)
  • December 2022 (16)
  • November 2022 (11)
  • October 2022 (14)
  • September 2022 (1)
  • August 2022 (4)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid bayer biontech cancer commission companies coronavirus covid-19 covid19 economy elpais.com emergency eu europe european fda food global guarantee health hygiene investment links medical merck novartis pandemic pfizer production recommendations region response roche safety scheme sector spain state statistics support test vaccine who

Copyright © 2023 | WordPress Theme by MH Themes

Cookie Consent with Real Cookie Banner